Elanco divests canine ear treatment in $135-million dealJanuary 6, 2020A major player in the animal health industry has just unloaded its proprietary treatment for canine otitis externa in an all-cash deal, totaling $135 million.
SPONSORED CONTENTStart Treating Canine MMVD Patients at Stage B2Learn about early treatment with pimobendan for canine Stage B2 preclinical MMVD patients. + Learn More